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 ABSTRACT 
Hyperlipidemia or hyperlipoproteinemia involves abnormally elevated levels of any or all lipids and/or 
lipoproteins in the blood. It has been proved beyond doubt that hyperlipidemia is one of the major 
modifiable risk factors for cardiovascular diseases. Statins are mostly preferred in the clinical management 
of hyperlipidemia. But in situations where the desired results are not achieved in spite of adequate statin 
therapy or statins are contraindicated or not tolerated, the physicians seek for a safer and effective 
alternative. Many herbal products have been studied extensively for their anti-hyperlipidaemic properties. 
Guggulu (Commiphora mukul), Rasona (Allium sativum) etc are few examples out of them.  
In this comparative clinical study a poly herbal formulation (Cholest Guard) was clinically evaluated in 27 
patients with hyperlipidemia. 25 patients in the control group were treated with Atorvastatin. Both Cholest 
Guard and Atorvastatin significantly reduced total cholesterol, LDL, VLDL and triglyceride levels and 
increased HDL level. The results were comparable. Cholest Guard was safe and devoid of any adverse 
effects. However Atorvastatin produced undue side effects like muscle pain, headache, nausea, sleep 
disturbance& Gastric upset. The LFT profile was also altered in some cases showing that Atorvastatin has 
deleterious effect on the liver. 
KEYWORDS: Hyperlipidemia, Polyherbal formulation, Cholest Guard, Atorvastatin, comparative, Clinical 
Study. 
INTRODUCTION 
 In the current century our life style has been 
totally distorted. Physical inactivity, unhealthy diet and the 
harmful use of alcohol and tobacco has resulted in many 
fatal outcomes for health. Hyperlipidemia is one such 
outcome. Hyperlipidemia or hyperlipoproteinemia 
involves abnormally elevated levels of any or all lipids 
and/or lipoproteins in the blood[1]. In other words 
hyperlipidemia can also be defined as raised serum levels 
of cholesterol or triglyceride or both of these. According to 
a US based survey hyperlipidemia came second followed 
by hypertension in a list of 10 most common chronic 
conditions that were encountered by primary health care 
providers[2]. It has been proved beyond doubt that 
hyperlipidemia is one of the major modifiable risk factors 
for cardiovascular diseases [3]. This is because raised blood 
cholesterol levels lead to atherosclerosis, a condition in 
which the arterial walls are thickened due to deposition of 
fatty materials. This was proved by Anitschkow and 
Chaltow way back in 1913 in their experimental study on 
rabbits[4]. Hyperlipidemia is estimated to cause 18% of 
global cerebrovascular disease (mostly nonfatal events) 
and 56% of global ischaemic heart disease which amounts 
to about 4.4 million deaths (7.9% of total) and 40.4 million 
disease adjusted life years or DALYs (2.8% of total) [5]. A 
landmark study that helped establish that therapeutic 
interventions to lower cholesterol levels result in reduced 
risk of cardiovascular morbidity or mortality was the Lipid 
Research Clinics Coronary Primary Prevention Trial which 
was published in two parts [6,7]. This is why doctors pay 
considerable focus in diagnosing and treating 
hyperlipidemia in order to prevent cardiovascular events. 
Statins are the preferred class of drugs to lower elevated 
low density lipoprotein cholesterol augmented by 
ezetimibe, fibrates, niacin and dietary supplements. But 
there are cases where lipid goals are not met in spite of 
maximal statin therapy. There are also situations where 
statins are contraindicated or not tolerated. So there is 
always a therapeutic scope for alternative remedies in 
hyperlipidemia. Many patients prefer herbal medicines to 
allopathic pharmaceutical products as they are less 
expensive to purchase, are effective and safe. However 
studies in this area are scanty.  
 There is no direct description of hyperlipidemia in 
Ayurvedic texts. However Ayurvedic researchers have 
described hyperlipidemia as “santarpanajanya vyadhi” or 
disease due to defective nutrition where there is increase 
of “asthayi medodhatu”. [8] 
 Since there is not enough published research on 
this topic, we undertook the current study with an effort to 
evaluate the efficacy of a polyherbal formulation (Cholest 
Guard) in hyperlipidemia.  
MATERIALS & METHODS 
 Patients attending the OPD of PG Department of 
Kayachikitsa in Gopabandhu Ayurveda Mahavidyalaya, 
Puri, Odisha were screened for their lipid profile 
irrespective of their sex, religion, cast etc. Only those 
patients who fulfilled the inclusion criteria and were ready 
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to give informed consent for the study were registered for 
the trial. A specially designed research case sheet was used 
for collecting and maintaining different data. 30 patients 
were randomly allocated to the trial group (TG) and were 
treated with the trial drug (Cholest Guard Capsule) for a 
period of three months. 30 patients were also randomly 
allocated to the control group (CG) and were treated with 
the control Drug (Atorvastatin). Randomization was done 
by computerized Random number generator. The entire 
study was completed in a span of six months (September 
2013 to February 2014). 
Inclusion Criteria 
Patients were diagnosed basing on their lipid profile 
reports with the following criteria. 
 Age group: 20 -60 years. 
 BMI < 40 
Satisfying one or more of the following criteria 
 Total cholesterol 201 mg/dl or more 
 Serum Triglycerides 151 mg/dl or more 
 Serum LDL 131 mg/dl or more 
 Serum VLDL 41 mg/dl or more 
Exclusion Criteria 
Patients with the following conditions were excluded from 
the study. 
 Secondary hyperlipidemia 
 Drug induced hyperlipidemia 
 Chronic Alcoholics 
 Patients with diabetes 
 Patients with renal insufficiency 
 Patients with serious cardiac disorders 
 Pregnant women & lactating mothers 
Concomitant Medication 
 Concomitant medications were monitored 
throughout the study and recorded in the research case 
sheet. Twenty one patients took no other drugs, 6 took 
antihistamines or anti-allergic preparations, 2 took 
laxatives, 3 took non-steroidal anti-inflammatory drugs 
(NSAID), 4 took antacids, and 4 took antibiotics. Most of 
these medications were taken for very short periods. None 
of the patients took any known lipid lowering medication 
other than trial drug and control drug. 
Investigations 
 All patients were investigated for their Lipid 
profile, Routine haematological tests, Fasting Blood Sugar 
(FBS), Postprandial Blood Sugar (PPBS), Serum Urea, 
Serum Creatinine & Liver Function Test before starting 
and after the completion of the trial. All the tests were 
performed in NABL accredited laboratory. 
Study Design 
 The current study was a randomized, standard 
controlled, comparative clinical trial.  
Ethical Clearance 
 The study was started after obtaining the approval 
of the Institutional Ethical Committee (IEC). 
 
 
Drugs and Posology 
Trial Drug 
 Cholest Guard Capsule (composition given below) 
was orally administered to the patients in the trial group in 
a dose of 2 capsules twice in a day after food with 
lukewarm water for a period of 3 months. 
Composition of Cholest Guard 
Each Capsule contains 
Guggulu Purified (Commiphora mukul) : 125 mg 
Ghanasatwa of Arjun Chhal (Terminalia arjuna) : 100 mg 
Lashun (Allium sativum) : 125 mg 
Sunthi (Zingiber officinale) : 50 mg 
Chai (Camellia sinensis) : 100 mg 
Excipients (Talc) : q.s 
Control Drug 
 Atorvastatin Tablet of strength 10 mg each was 
orally administered to the patients of control group once 
daily with plain water for a period of 3 months. 
Dietary & Exercise Advice (Pathyapathya) 
 All the patients were advised to follow a specific 
diet plan in order to maintain a fairly uniform dietary 
pattern and the compliance was assured by routine 
interview by the investigators during the fortnightly follow 
up visits. They were advised to stop smoking and avoid 
certain foods containing high saturated fat. They were 
instructed to do brisk walking for 30 minutes at least 5 
days a week during the therapy period. 
Assessment of the Study 
Criteria of Assessment 
 Since hyperlipidemia is mostly asymptomatic, the 
study was assessed using objective criteria alone. The 
following objective criteria were fixed for assessment of 
the study. 
 Complete lipid profile including Total serum 
Cholesterol, High Density Lipoproteins (HDL), Low Density 
Lipoprotein (LDL), Very Low Density Lipoproteins (VLDL) 
and Triglyceride (TG) was done for every patient included 
in the trial before starting and after completion of the 
study. Change in these parameters were analysed to get 
the outcome of the study by using suitable statistical 
method. The normal reference range for different 
components of lipid profile was fixed as per the guideline 
of Medline Plus Medical Encyclopedia (An online service 
provided by the U.S. National Library of Medicine & 
National Institutes of Health. [9] 
Statistical Analysis 
 The values of different components of lipid profile 
before and after treatment were compared using Students 
Paired t-test. If the p – value was found to be < .05 the 
result was interpreted as insignificant. If the p – value was 
found to be < .01 the result was interpreted as significant. 
If the p – value was found to be < .001 the result was 
interpreted as extremely significant. All the calculations 
were done by using Graphpad statistical software. 
 The overall benefit of the therapy was assessed by 
a specially designed scoring system. A percentage change 
in before treatment (BT) & after treatment (AT) was 
calculated for each of the components of Lipid Profile i.e. 
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Total Cholesterol, HDL, LDL, VLDL & TG for every patient. 
A corresponding score equal to the percentage change was 
assigned for each observation. These individual scores 
were added to get a total score. The total score was 
interpreted as per the following. 
 Scores > 100 – Excellent Result 
 Scores between 61 to 100 – Good Result 
 Scores between 21 to 60 – Satisfactory Result 
 Scores ≤ 20 – Unsatisfactory Result 
 For Example, if a patient has undergone a 
percentage change of 10%, 15%, 20%, 25% & 30% in Total 
Cholesterol, HDL, LDL, VLDL & TG respectively after 
treatment in comparison to their baseline (BT) values then 
their corresponding scores will be 10, 15, 20, 25 & 30 in 
order. These Scores are added together to get a total score 
of 100 and the overall result will be interpreted as “Good”.  
OBSERVATIONS & RESULT 
 Initially we registered 30 patients in each Trial 
Group (TG) & Control Group (CG). But there was a drop out 
of 3 and 5 patients from TG and CG respectively due to 
different reasons. Therefore 27 patients from TG and 25 
patients from CG completed the trial.  
Demographic Data & Observations Related to Risk 
Factors 
 The study included both male and female patients. But 
males dominated female patients. 
 The study included both Vegetarians and Non - 
vegetarians. But Non - Vegetarians clearly 
outnumbered the Vegetarians in both TG & CG. 
 It was alarming that 89 % patients in the TG and 96 % 
patients in the CG were having some or the other 
addiction. However alcoholics were maximum 
followed by Cannabis and Tobacco users. 
 Hyperlipidemia was found to be well distributed in 
different BMI groups. But we did not come across any 
underweight patient. The saliency of overweight 
patients was maximum followed in order by normal 
weight, Class – 1 obesity & Class – 2 obesity. 
Observations Related to Effectiveness of Trial Drug and Control Drug 
 
Overall Assessment of Effectiveness of Trial Drug & Control Drug 
 
Parameter Mean ± S.D. ↑↓
d.f.       
(n-1)
t-Value p-Value Remarks
BT 210.09 ± 28.45 26
AT 187.31 ± 21.28 26
BT 234.18 ± 29.46 24
AT 196.37 ± 19.92 24
BT 43.53 ± 7.19 26
AT 50.75 ± 6.54 26
BT  45.23 ± 7.84 24
AT 47.32 ± 5.64 24
BT 137.65 ± 25.62 26
AT 108.72 ± 19.83 26
BT 144.32 ± 18.89 24
AT 116.55 ± 13.71 24
BT 45.09 ± 9.91 26
AT 27.84 ± 5.44 26
BT 44.16 ± 17.26 24
AT 32.48 ± 11.38 24
BT 175.44 ± 49.54 26
AT 139.57 ± 28.01 26
BT 222.11 ± 82.38 24
AT 162.43 ± 56.93 24
VLDL
TG 4.31 < 0.0001
Extremely 
Significant
CG 2.64 0.0142 Significant
4.29 < 0.0001
Extremely 
Significant
CG
LDL
TG 3.19 0.0036
Very 
Significant
CG 5.35 < 0.0001
Extremely 
Significant↓
HDL
TG 4.68 < 0.0001
Extremely 
Significant
CG 1.11 0.2691 Not Significant
2.84 0.0089
Very 
Significant
Table 1 : Effectiveness of Trial Drug & Control Drug
Total 
Cholesterol
TG 4.94 < 0.0001
Extremely 
Significant
CG 4.99 < 0.0001
Extremely 
Significant
Triglyceride
TG
↓
↓
↓
↓
Group
↓
↓
↑
↑
↓
No. of 
Patients
Percentage
No. of 
Patients
Percentage
Excellent 10 37% 9 36%
Good 12 45% 10 40%
Satisfactory 3 11% 5 20%
Unsatisfactory  2 7% 1 4%
Trial Group Control Group
Table 2 : Overall Assessment of results after treatment 
Overall 
Assessment 
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 Both Cholest Guard (Trial Drug) & Atorvastatin 
(Control Drug) were found effective in reducing Total 
Cholesterol level. The Total Cholesterol reduced from 
210.09 ± 28.45 mg/dl to 187.31 ± 21.28 mg/dl in the 
TG taking Cholest Guard. Reduction in Total 
Cholesterol from 234.18 ± 29.46 mg/dl to 196.37 ± 
19.92 mg/dl occured in CG taking Atorvastatin. Both 
the results were found to be extremely significant (p 
< 0.0001). 
 HDL Cholesterol was found to increase after 
treatment in both the groups. In the TG, Cholest 
Guard increased HDL from 43.53 ± 7.19 mg/dl to 
50.75 ± 6.54 mg/dl and the result was extremely 
significant (p < 0.0001). In the CG, Atorvastatin also 
increased HDL from 45.23 ± 7.84 mg/dl to 47.32 ± 
5.64 mg/dl. However this marginal increase of HDL in 
the CG was not found statistically significant (p = 
0.2691). 
 Both Cholest Guard & Atorvastatin reduced the LDL 
level in TG & CG respectively. It was reduced from 
137.65 ± 25.62 mg/dl to 108.72 ± 19.83 mg/dl in TG 
& it was also reduced from 144.32 ± 18.89 mg/dl to 
116.55 ± 13.71 mg/dl in CG. Statistically the results 
were very significant in TG (p = 0.0036) & extremely 
significant in CG (p < 0.0001) 
 VLDL was reduced after treatment in both the 
groups. Cholest Guard reduced VLDL from 45.09 ± 
9.91 mg/dl to 27.84 ± 5.44 mg/dl in TG where as 
Atorvastatin reduced it from 44.16 ± 17.26 mg/dl to 
32.48 ± 11.38 mg/dl in CG. Statistically, the changes 
were found to be extremely significant in TG (p < 
0.0001) and significant in CG (p = 0.0142) 
respectively. 
 Serum Triglyceride was found to be reduced from 
175.44 ± 49.54 mg/dl to 139.57 ± 28.01 mg/dl in TG 
who were taking Cholest Guard and it was also found 
to be reduced from 222.11 ± 82.38 mg/dl to 162.43 ± 
56.93 mg/dl in CG who were taking Atorvastatin. 
Statistically, the changes were extremely significant 
in TG (p < 0.0001) & very significant in CG (p = 
0.0089). 
 On overall assessment of the effectiveness of Cholest 
Guard & Atorvastatin in hyperlipidemia we got the 
following results. Cholest Guard gave Excellent 
results in 37 % cases, Good result in 45 % cases, 
Satisfactory results in 11 % cases and Unsatisfactory 
results in 7 % cases where as Atorvastatin gave 
Excellent results in 36 % cases, Good result in 40 % 
cases, Satisfactory results in 20 % cases and 
Unsatisfactory results in 4 % cases. 
Observations Related to Incidence of Adverse Effects 
 On analysing the incidence of adverse effects we got 
that Cholest Guard did not produce any unwanted or 
adverse effect except only one incidence of Gastric 
upset for very short period.  
 Cholest Guard did not alter the Liver Function & 
Renal Function Profile proving that it has no 
deleterious effect on vital organs.  
 On the other hand Atorvastatin caused various 
adverse effects like muscle pain in 3 cases, headache 
in 4 cases, Nausea in 2 cases, sleep disturbance in 5 
cases & Gastric upset in 7 cases.  
 In the control group (CG) the Liver Function Test 
(LFT) profile was altered in 7 cases showing that 
Atorvastatin has deleterious effect on the liver. 
However it did not altered the Renal function. 
DISCUSSION 
 The male patients dominated the female patients 
in the study. This may be due to the reasons that males are 
more addicted to tobacco & alcohol and their food habit is 
more conducive for hyperlipidemia. Since in the state like 
Odisha males get better medical facility than females, their 
foot fall might have been more during the trial period. 
 Patients in the age group of 41 – 50 were 
maximum in the trial indicating that hyperlipidemia is 
more prevalent in this age group. This may be due to the 
fact that these years in life are more stressful years. So 
there is every chance of altered dietary habits and getting 
addicted to alcohol or tobacco which might have facilitated 
the process of hyperlipidemia. 
 The Desk work professionals and people with 
intellectual field work were more in number in this trial. 
Their sedentary life style may be held responsible for 
accelerating hyperlipidemia. 
 Non – vegetarian food contains more saturated 
fats in comparison to Vegetarian foods. This may be the 
reason why the incidence of Non – Vegetarians was more 
than Vegetarians in this study. 
 Most of the patients were having some addiction 
or the other. High incidence of alcohol & tobacco users 
proves that these are potential risk factors for 
hyperlipidemia. 
 Contrary to the common belief that only obese 
patients are more likely to have hyperlipidemia, we found 
that non obese (over weight) & even normal weight 
patients also suffer from hyperlipidemia. Therefore 
hypercholesterolemia necessarily does not depend on 
body fat. 
 Both Cholest Guard and Atorvastatin were found 
effective in reducing Total Cholesterol, LDL, VLDL & 
Triglyceride and the results were comparable. However 
the raise in HDL was found much better in TG taking 
Cholest Guard. Pharmacologically Atorvastatin can also 
raise serum HDL level. In this study the raise in HDL in CG 
taking Atorvastatin was not statistically significant. This 
may be explained on the fact that the HDL elevating 
property of Atorvastatin is dose dependant. In this study 
we used only 10 mg of Atorvastatin once in a day. The 
result would have been better with higher doses. 
 The overall effectiveness of Cholest Guard and 
Atorvastatin is also comparable. 
 But these two drugs differ greatly in terms of their 
adverse effects. Cholest Guard did not produce any adverse 
effect except gastric upset in only one patient for a very 
short period in the beginning of the therapy. This may be 
due to the reason that the particular patient usually does 
not take onion and garlic in his food. Garlic which is an 
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ingredient of Cholest Guard might have caused some 
problem in the beginning and after few days the problem 
automatically subsided. On the other hand Atorvastatin 
produced many adverse effects like muscle pain, nausea, 
headache, sleep disturbance & gastric upsets in 
considerable number of cases.  
 Liver Function Profile and Renal function profile 
were not at all altered in the TG taking Cholest Guard 
proving that the drug do not produce harmful effects on 
vital organs where as Atorvastatin altered the LFT in 7 
cases showing its hepatotoxicity. However it does not 
produce any harmful effect on the Renal function. 
 Considering the effectiveness & adverse effects of 
both Cholest Guard & Atorvastatin in managing 
hyperlipidemia, we can say that the former has many 
advantages over the later. Cholest Guard has unique ability 
to manage hyperlipidemia without causing any adverse 
effect or deleterious effect on the vital organs. 
Possible Mode of Action of Cholest Guard 
 Cholest Guard is an unique formulation containing 
Guggulu Purified (Commiphora mukul) - 125 mg, 
Ghanasatwa of Arjun Chhal (Terminalia arjuna) - 100 mg, 
Lashun (Allium sativum) - 125 mg, Sunthi (Zingiber 
officinale) - 50 mg & Chai (Camellia sinensis) - 100 mg. Each 
of these drugs has been proved to have antihyperlipidemic 
effect in several experimental & human trials. 
 Different mechanisms has been proposed to 
explain the antihyperlipidemic effect of Guggulu. It may 
decrease hepatic steroid production and increase the 
catabolism of LDL cholesterol.[10] Another mechanism is 
that the proposed guggulsterones E and Z (active 
components of Guggul), may increase hepatic binding sites 
for LDL cholesterol thereby increasing LDL clearance.[11] 
One more mechanism is prevention of cholesterol 
synthesis in the liver by ketonic steroids.[12] 
Guggulsterones E and Z act as antagonists at the farnesoid 
X receptor which causes more cholesterol catabolism and 
excretion from the body. This receptor mediates the 
conversion of cholesterol to bile acids. When this receptor 
is antagonized, 7α-hydroxylase is released and cholesterol 
catabolism is stimulated. [12, 13] 
 Garlic acts as an antihyperlipidemic agent by 
depressing the hepatic activities of cholesterogenic 
enzymes such as malic enzyme, fatty acid synthase, 
glucose-6 phosphate dehydrogenase (G-6 PD) and 3-
hydroxy-3-methyl-glutaryl-CoA (HMG CoA) reductase. [14] 
Garlic also increases the excretion of Cholesterol. [15] 
Water-soluble organosulfur compounds present in garlic, 
especially S-allyl cysteine (SAC) & Diallyl di-sulfide (DADS) 
are also potent inhibitors of cholesterol synthesis. [14] 
 Terminalia arjuna acts as a lipid lowering agent by 
inhibition of hepatic cholesterol biosynthesis, increased 
faecal bile acid excretion, and stimulation of receptor-
mediated catabolism of LDL cholesterol. [16, 17, 18] 
 Constituents within ginger inhibit the process of 
cholesterol biosynthesis.[19] Ginger also enhances the 
activity of hepatic cholesterol 7α-hydroxylase, the rate 
limiting enzyme in bile acids biosynthesis, thereby 
stimulating cholesterol conversion to bile acids and thus 
cholesterol is eliminated from human body. [20] 
 Active principles in tea increase the expression of 
hepatic LDL-C receptor –A cell surface protein which 
controls the plasma cholesterol and increase the faecal 
excretion of bile acids and Cholesterol. [21] 
CONCLUSION 
 As per the results of this study, both Cholest Guard 
& Atorvastatin significantly reduced Total Cholesterol, 
LDL, VLDL & Triglyceride with comparable results. Since 
Atorvastatin produced considerable incidence of adverse 
effects and altered the Liver function in many cases, 
therefore Cholest Guard would definitely be a safer choice 
in managing hyperlipidemia. 
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